Sara A. Byron

3.3k total citations · 1 hit paper
48 papers, 1.9k citations indexed

About

Sara A. Byron is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sara A. Byron has authored 48 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 19 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sara A. Byron's work include Cancer Genomics and Diagnostics (15 papers), Fibroblast Growth Factor Research (13 papers) and Glioma Diagnosis and Treatment (6 papers). Sara A. Byron is often cited by papers focused on Cancer Genomics and Diagnostics (15 papers), Fibroblast Growth Factor Research (13 papers) and Glioma Diagnosis and Treatment (6 papers). Sara A. Byron collaborates with scholars based in United States, Australia and Canada. Sara A. Byron's co-authors include John D. Carpten, David W. Craig, Pamela M. Pollock, Kendall Van Keuren‐Jensen, David M. Engelthaler, Michael G. Gartside, Candice L. Wellens, Paul J. Goodfellow, Matthew A. Powell and David G. Mutch and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Nature Reviews Genetics.

In The Last Decade

Sara A. Byron

47 papers receiving 1.9k citations

Hit Papers

Translating RNA sequencing into clinical diagnostics: opp... 2016 2026 2019 2022 2016 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Translating RNA sequencing into clinical diagnostics: opportunities and challenges
    2016 504 citations Sara A. Byron, Kendall Van Keuren‐Jensen et al. Nature Reviews Genetics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sara A. Byron United States 18 1.3k 549 375 223 179 48 1.9k
Bin Shi China 10 1.2k 0.9× 606 1.1× 852 2.3× 271 1.2× 105 0.6× 16 2.1k
Anne M. Øyan Norway 37 1.6k 1.3× 769 1.4× 809 2.2× 410 1.8× 163 0.9× 75 2.9k
Hena R. Ashar United States 12 1.2k 0.9× 380 0.7× 522 1.4× 150 0.7× 122 0.7× 13 1.6k
Esra A. Akbay United States 23 910 0.7× 299 0.5× 582 1.6× 196 0.9× 202 1.1× 34 1.6k
Elisabeth Mueller‐Holzner Austria 18 1.5k 1.1× 523 1.0× 679 1.8× 118 0.5× 187 1.0× 31 2.1k
Yusuke Nakamura Japan 27 1.5k 1.1× 627 1.1× 773 2.1× 352 1.6× 468 2.6× 84 2.7k
Stefanie Avril United States 22 649 0.5× 418 0.8× 801 2.1× 189 0.8× 126 0.7× 45 1.7k
Kae Hashimoto Japan 27 1.2k 0.9× 781 1.4× 632 1.7× 183 0.8× 112 0.6× 73 2.1k
David Cogdell United States 27 1.8k 1.4× 1.2k 2.1× 477 1.3× 328 1.5× 104 0.6× 47 2.6k
Nikita Makretsov Canada 14 682 0.5× 380 0.7× 593 1.6× 164 0.7× 195 1.1× 19 1.4k

Countries citing papers authored by Sara A. Byron

Since Specialization
Citations

This map shows the geographic impact of Sara A. Byron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara A. Byron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara A. Byron more than expected).

Fields of papers citing papers by Sara A. Byron

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara A. Byron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara A. Byron. The network helps show where Sara A. Byron may publish in the future.

Co-authorship network of co-authors of Sara A. Byron

This figure shows the co-authorship network connecting the top 25 collaborators of Sara A. Byron. A scholar is included among the top collaborators of Sara A. Byron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara A. Byron. Sara A. Byron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Chan, Agnes P., Yongwook Choi, Guangfa Zhang, et al.. (2022). Interrogating the Human Diplome: Computational Methods, Emerging Applications, and Challenges. Methods in molecular biology. 2590. 1–30. 1 indexed citations
4.
Halperin, Rebecca F., Winnie S. Liang, Erica E. Tassone, et al.. (2019). Leveraging Spatial Variation in Tumor Purity for Improved Somatic Variant Calling of Archival Tumor Only Samples. Frontiers in Oncology. 9. 119–119. 10 indexed citations
5.
Roos, Alison & Sara A. Byron. (2019). Genomics-Enabled Precision Medicine for Cancer. Cancer treatment and research. 178. 137–169. 6 indexed citations
6.
Liang, Winnie S., Christopher Dardis, Adrienne Helland, et al.. (2018). Identification of therapeutic targets in chordoma through comprehensive genomic and transcriptomic analyses. Molecular Case Studies. 4(6). a003418–a003418. 14 indexed citations
7.
Weiss, Glen J., Sara A. Byron, Jessica Aldrich, et al.. (2017). A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy. PLoS ONE. 12(6). e0179170–e0179170. 8 indexed citations
8.
Jeske, Y., Shamshad Ali, Sara A. Byron, et al.. (2017). FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 145(2). 366–373. 41 indexed citations
9.
Becker, Marc A., Yasir H. Ibrahim, Annabell S. Oh, et al.. (2016). Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. PLoS ONE. 11(3). e0150564–e0150564. 12 indexed citations
10.
Byron, Sara A., Kendall Van Keuren‐Jensen, David M. Engelthaler, John D. Carpten, & David W. Craig. (2016). Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nature Reviews Genetics. 17(5). 257–271. 504 indexed citations breakdown →
11.
Prados, Michael D., Sara A. Byron, Nhan L. Tran, et al.. (2015). Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-Oncology. 17(8). 1051–1063. 157 indexed citations
12.
Doudican, Nicole, Sara A. Byron, Pamela M. Pollock, & Seth J. Orlow. (2012). XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. Anti-Cancer Drugs. 24(2). 181–188. 2 indexed citations
13.
Byron, Sara A., Elizabeth Min, Galen Hostetter, et al.. (2012). Negative Regulation of NF-κB by the ING4 Tumor Suppressor in Breast Cancer. PLoS ONE. 7(10). e46823–e46823. 38 indexed citations
14.
Byron, Sara A., Michael G. Gartside, Matthew A. Powell, et al.. (2012). FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features. PLoS ONE. 7(2). e30801–e30801. 140 indexed citations
15.
Byron, Sara A., David Loch, & Pamela M. Pollock. (2012). Fibroblast Growth Factor Receptor Inhibition Synergizes With Paclitaxel and Doxorubicin in Endometrial Cancer Cells. International Journal of Gynecological Cancer. 22(9). 1517–1526. 1 indexed citations
16.
Byron, Sara A., Michael G. Gartside, Candice L. Wellens, et al.. (2010). FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecologic Oncology. 117(1). 125–129. 37 indexed citations
17.
Gartside, Michael G., Huaibin Chen, Omar A. Ibrahimi, et al.. (2009). Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma. Molecular Cancer Research. 7(1). 41–54. 102 indexed citations
18.
Kalinina, Juliya, Sara A. Byron, Helen P. Makarenkova, et al.. (2009). Homodimerization Controls the Fibroblast Growth Factor 9 Subfamily's Receptor Binding and Heparan Sulfate-Dependent Diffusion in the Extracellular Matrix. Molecular and Cellular Biology. 29(17). 4663–4678. 38 indexed citations
19.
Byron, Sara A., Michael G. Gartside, Candice L. Wellens, et al.. (2008). Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation. Cancer Research. 68(17). 6902–6907. 119 indexed citations
20.
Gartside, Michael G., Sara A. Byron, Candice L. Wellens, et al.. (2007). Inhibition of FGFR2 in endometrial cancer cells induced apoptosis despite constitutive activation of the PI3K/AKT pathway.. Molecular Cancer Therapeutics. 6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bin Shi Breakdown of academic impact, for papers by Anne M. Øyan Breakdown of academic impact, for papers by Hena R. Ashar Breakdown of academic impact, for papers by Esra A. Akbay Breakdown of academic impact, for papers by Elisabeth Mueller‐Holzner Breakdown of academic impact, for papers by Yusuke Nakamura Breakdown of academic impact, for papers by Stefanie Avril Breakdown of academic impact, for papers by Kae Hashimoto Breakdown of academic impact, for papers by David Cogdell Breakdown of academic impact, for papers by Nikita Makretsov
Rankless by CCL
2026